Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | test | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
Test |
sfgd |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Janssen Partners with Evotec-Harvard Diabetes Collaboration ProgramJanssen Pharmaceutical a division of Johnson & Johnson has entered into partnership with Harvard University - Evotec's Diabetes program called CureBeta. Janssen will paying $300million in milestone payments per product in addition to $8million in... View all Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all |
No EVENTS for listing |
No Job Posts |
